企業概要
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical entity within the United States, focusing on developing product candidates such as PEDMARK, a sodium thiosulfate formulation designed to prevent cisplatin-induced ototoxicity in pediatric patients. The company functions within the Healthcare sector and specifically the Biotechnology industry, a segment characterized by high research and development costs and significant regulatory hurdles before products reach commercialization. FENC currently lists with a market capitalization of $220.64M, generates $44.64M in annual revenue, and employs a workforce of 35 individuals. These valuation and revenue figures indicate that the company maintains a mid-cap status, suggesting it has achieved sufficient commercial traction to generate substantial sales yet remains in a growth phase where earnings are not yet positive enough to support a large market valuation. The scale of the operation, reflected in its $44.64M revenue stream, positions it as a specialized player in the oncology support market, while the $220.64M market cap reflects investor confidence in its pipeline potential despite the absence of profitability.
財務健全性
The company reported revenue of $44.64M over the trailing twelve months, yet recorded a net income of $-9,741,000 and an EBITDA of $-6,179,333, revealing a significant gap between top-line sales and bottom-line profitability that points to high operational expenses or R&D costs typical of the biotechnology sector. The free cash flow stands at $-7,332,250, indicating that the company is currently burning cash, which limits its immediate financial flexibility for capital expenditures or acquisitions without external funding. Gross margin is reported at 91.6%, demonstrating strong pricing power or low cost of goods sold, whereas the operating margin is -18.5% and the profit margin is -21.8%, highlighting that fixed costs and operating expenses are currently consuming a large portion of the revenue. The balance sheet shows $36.79M in cash and $0 in debt, meaning the company holds a substantial cash reserve relative to its liabilities. With a debt-to-equity ratio listed as N/A due to the absence of debt, the capital structure is entirely equity-funded, presenting a conservative stance with no interest burden. The current ratio is 6.37, which signifies a very strong short-term liquidity position, providing ample ability to cover current liabilities with current assets. Furthermore, the return on equity is -65.8% and the return on assets is -6.8%, metrics that reveal that management is currently not generating positive returns on shareholder capital or total assets, a common characteristic for unprofitable growth-stage biotech firms.
バリュエーション評価
The trailing P/E ratio is N/A because the company is not profitable, while the forward P/E is 7.07, implying that the market expects earnings to turn positive in the future based on projected performance. The price-to-book ratio is 6.17, indicating that the market values the company at more than six times its book value, which suggests a premium pricing for its intangible assets, patent portfolio, and growth potential. The price-to-sales ratio is 4.94 and the EV/EBITDA is -29.75, suggesting that valuation is primarily driven by revenue multiples rather than earnings power, a common approach for companies with negative earnings. The stock traded between a 52-week low of $4.68 and a 52-week high of $9.92, placing the current trading price within this historical range and reflecting recent market volatility. The beta value is 0.93, indicating that the stock's price volatility is roughly in line with the broader market, showing neither excessive aggression nor defensiveness compared to the S&P 500. These metrics collectively suggest that investors are pricing in significant future growth potential to justify the current share price despite the lack of current earnings.
Growth & Income
Revenue growth year-over-year is 73.8%, while earnings growth is N/A due to the company's unprofitable status, implying that top-line expansion is occurring without corresponding immediate profit generation. The company does not pay dividends, as indicated by a dividend yield of N/A and a payout ratio of 0.0%, meaning it retains all earnings to fund operations and growth initiatives rather than distributing cash to shareholders. This reinvestment strategy is typical for biotechnology firms that prioritize funding their pipeline over returning capital to investors. The overall growth and income profile is defined by rapid revenue expansion coupled with significant cash burn and no dividend distribution, creating a high-risk, high-reward investment scenario reliant on future product approvals and commercial success.